Miglustat hydrochloride

Research use only, not for human use.

Miglustat hydrochloride is an inhibitor of glucosylceramide synthase and can be used for studies about Type I Gaucher disease.

Miglustat hydrochloride is an inhibitor of glucosylceramide synthase and can be used for studies about Type I Gaucher disease. (In Vivo):Consumption of a standard high-fat breakfast within 30 minutes before administration of Miglustat hydrochloride significantly reduced peak exposure but did not significantly affect the extent of systemic exposure to Miglustat hydrochloride. The Cmax decreased by 36% on average following administration with food. AUC showed a modest (14%) decrease with food, but the 90% confidence interval was within the acceptance limit of 80% to 125%. Tmax was prolonged from 2.5 (1.0-4.0) hours in the fasted state to 4.5 (1.5-8.0) hours in the fed state, whereas the apparent terminal half-life was approximately 8 hours and not affected by food.

——

Mi Animal Model:NPC1?/? mice Dosage:0.2?mg/kg Administration:Oral administration; once Result:Was able to rescue synaptic plasticity deficits, to restore ERKs activation and to counteract hyperexcitability.

NB-DNJ hydrochloride | OGT918 hydrochloride | N-Butyldeoxynojirimycin hydrochloride

Metabolic Enzyme/Protease

Transferase

Transferase

——

——

210110-90-0

255.74

C10H22ClNO4

>98% (HPLC)

In Vitro:?DMSO : 65 mg/mL (254.16 mM)

Cl.CCCCN1CC(O)[C@@H](O)C(O)C1CO

——

(-20℃)

With Ice Pack

≥ 2 years